Transvaginal Mesh Lawsuits – Who Is At Fault?

For some women a pelvic transvaginal mesh product has been a god sent.  To be able to resume a full active life, without the worry of a leaky bladder, is a true miracle for some women.  And, this only became possible with the help of pelvic mesh.

The mesh is most commonly used after pelvic organ prolapse, or when muscles in the area weaken, causing organs to bulge or slip down into the vagina. It can happen because of age, childbirth or other reasons and can cause pain and bladder leakage. It is also used to treat stress urinary incontinence.

But, for others the mesh itself has caused more pain and trouble than the pelvic organ prolapse that they started with.  Many women allege they sustained serious, painful and life-changing injuries following implantation of the vaginal mesh.

With pelvic mesh lawsuits on the rise, who is truly at fault- the product, manufacturer, or surgeon implanting device?

When pelvic mesh products were introduced, they were seen as a high-tech improvement over traditional surgery using stitches and a woman’s own body tissue, which also can have complications. Since similar mesh was already used in other types of surgery, including for repairing hernias as far back as the 1950s, the products received fast-track approval from the FDA without the tests that the agency requires for first-of-a-kind devices.

The FDA cleared the mesh — often a soft, lightweight porous plastic — for pelvic organ prolapse in 2002, and the agency said in a 2008 public notice that problems were “rare.” In July 2011, however, the agency said it erred in its initial assessment and estimated the most common problems occur in 10 percent of women within a year of surgery.

The mesh can be inserted through the vagina or through an incision in the abdomen, though the latter is less common and has significantly fewer complications, the FDA said. The problems involve shifting and erosion of the mesh, as well as infections.

A year ago, the FDA ordered several dozen manufacturers to conduct rigorous studies to track the complication rates with their surgical mesh products over time. Some companies have undertaken those studies, while others chose to stop producing certain products.

Dr. Cheryl Iglesia, a surgeon in Washington who was on the FDA panel, said things have come a long way over the last year.  A national registry to track pelvic prolapse surgeries should help identify problems more quickly — whether they’re caused by patient complications, surgeons with inadequate experience or the mesh itself, she said.

Some doctors have also been reconsidering when to use the implantation, and the mesh products have become smaller and lighter, she said. She uses the newer, smaller mesh products on some of her patients.

“To some degree, the marketing of the mesh may have been ahead of the science,” she said.

Dr. Vincent Lucente, a Pennsylvania doctor who specializes in female reconstructive pelvic surgery, is among a group of doctors who have spoken out against the FDA’s warnings. The main problems with the mesh products are caused by surgeons who don’t have enough training, he said. Publicity from the lawsuits scares women into refusing treatment with the mesh even though they could benefit from it, he said.

“It is a tragic moment in our field where there’s public sentiment and perception being developed by lawyers and not by physicians,” he said. “The innovation — and the skill sets to use the innovation — is outpacing the skill sets that the surgeons have, and no one is trying to close that gap.”

Lucente believes there should be a credentialing process to ensure expertise, as there is for other surgical procedures.

You May Also Like


  • This field is for validation purposes and should be left unchanged.

, , , , , ,

No comments yet.

Leave a Reply

  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.